scholarly journals Stent strut ablation with rotational atherectomy device (Rotablator™) for restenosis treatment. Analysis and late follow-up

2020 ◽  
pp. 1-6
Author(s):  
Débora Rocha ◽  
Henrique Guimarães ◽  
Flávio Barbosa ◽  
Álvaro Morais Júnior ◽  
Roosevelt Diniz ◽  
...  
Keyword(s):  
Bare Metal Stents ◽  
Coronary Intervention ◽  
Rotational Atherectomy ◽  
Metal Stents ◽  
Stent Restenosis ◽  
Percutaneous Coronary ◽  
Stent Strut ◽  
In Stent Restenosis

The widespread use of bare metal stents as from 1995 led to the appearance of a new entity called in-stent restenosis, and the severe concomitant calcification of the vessels is a challenge for the interventional cardiologist. In this scenario, rotational atherectomy has rised as a therapeutic rescue approach to manage this situation, using trephines to eliminate the underexpanded and non-expandable coronary stents. However, comprehensive data on the long-term efficacy or results of the procedures have not been published yet. We report a case of rotational atherectomy in stent restenosis, followed by percutaneous coronary intervention with implantation of a new stent to treat a calcified in-stent lesion.

scholarly journals A Case of Very Early Stent Restenosis Following DES Implantation

2019 ◽  
Vol 04 (04) ◽  
pp. 200-203 ◽  
Author(s):  
Shravan Kumar Ch ◽  
Naveen Kumar M. ◽  
Sudhakar Kanumuri
Keyword(s):  
Bare Metal Stents ◽  
Coronary Intervention ◽  
Drug Eluting Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Stent Restenosis ◽  
Percutaneous Coronary ◽  
Drug Eluting ◽  
In Stent Restenosis ◽  
Stent Stenosis

AbstractIntracoronary in-stent restenosis (ISR) is more common with bare metal stents. With the introduction of drug-eluting stents (DESs), the incidence of ISR has markedly decreased. Here, we report a case of unusual very early stent restenosis in a patient who presented with unstable angina 15 days after percutaneous coronary intervention with sirolimus-eluting DES. Optical coherence tomography (OCT) was done to know the pathophysiology of the very early stent stenosis and the possibilities of the rare findings of this OCT are discussed.

Patient Selection and Procedural Considerations for Coronary Orbital Atherectomy System

2016 ◽  
Vol 11 (1) ◽  
pp. 33
Author(s):  
Yohei Sotomi ◽  
◽  
◽  
◽  
◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Coronary Intervention ◽  
Rotational Atherectomy ◽  
Percutaneous Coronary ◽  
Orbital Atherectomy ◽  
Long Term Follow Up ◽  
Coronary Lesions ◽  
Calcified Coronary Lesions

Despite advances in technology, percutaneous coronary intervention (PCI) of severely calcified coronary lesions remains challenging. Rotational atherectomy is one of the current therapeutic options to manage calcified lesions, but has a limited role in facilitating the dilation or stenting of lesions that cannot be crossed or expanded with other PCI techniques due to unfavourable clinical outcome in long-term follow-up. However the results of orbital atherectomy presented in the ORBIT I and ORBIT II trials were encouraging. In addition to these encouraging data, necessity for sufficient lesion preparation before implantation of bioresorbable scaffolds lead to resurgence in the use of atherectomy. This article summarises currently available publications on orbital atherectomy (Cardiovascular Systems Inc.) and compares them with rotational atherectomy.

In-stent restenosis in the drug-eluting stent era

2018 ◽  
pp. 453-472
Author(s):  
Jaya Chandrasekhar ◽  
Adriano Caixeta ◽  
Philippe Généreux ◽  
George Dangas ◽  
Roxana Mehran
Keyword(s):  
Low Frequency ◽  
Bare Metal Stents ◽  
Coronary Intervention ◽  
Drug Eluting Stent ◽  
Metal Stents ◽  
Pharmacological Agents ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
In Stent Restenosis

Since the inception of percutaneous coronary intervention, restenosis has been considered a significant problem. Although drug-eluting stents (DES) have reduced rates of in-stent restenosis (ISR) compared with bare metal stents across all lesion subsets, ISR has not been abolished. DES efficacy has been limited by suboptimal polymer biocompatibility, efficacy of pharmacological agents, in vivo pharmacokinetic properties, and local drug resistance and toxicity. While the first two DES to be manufactured (sirolimus- and paclitaxel-eluting stents) have the longest clinical follow-up, extensive data are now also available on zotarolimus- and everolimus-eluting stents. The uptake of biolimus-eluting stents has recently increased in clinical practice. Although the low frequency of DES ISR makes it difficult to investigate this condition fully, many studies have examined the mechanism, incidence, predictors, and optimal treatment of DES restenosis. This review discusses the data relevant to DES restenosis and the perspective on the current treatment of this condition.

Sign in / Sign up

Export Citation Format

Share Document